A group of researchers at Tashkent Medical Academy came to a conclusion that patients at the critical stage of myocardial infarction can be prescribed immune stimulators.
Presently, patients who suffered from myocardial infarction are at high risk of becoming disabled or dying mainly due to reoccurring irregularities of coronary blood circulation. Every instance of the disease affects the bodily functions and the immune system of the patient. During myocardial infarction along with irregularities in blood circulation of the heart muscle, immunological factors also play a big role. This fact was confirmed by clinical and experimental research.
A group of scientists at Tashkent Medical Academy, Kurbanova, Dushanbieva. Tashhanova and Buranova, conducted an evaluation of the indicator of the immune systems of patients with myocardial infarction in the dynamics of the disease, in order to improve the methods of helping these patients. The test group consisted of 65 patients who suffered from myocardial infarction within the age range of 40 to 68, who were hospitalized to the Department of Cardiology of the Tashkent Medical Academy and the Specialized Republican Centre within 24 hours from the moment of the disease.
According to the scientists, detecting the concentration of cytokines in the blood of patients with myocardial infarction helps to evaluate the level of activity of the disease and test the effects of therapy on the wellbeing of patients. The decisive factor in the diagnosis of these diseases is the measurement of the concentration of IL-6 and IL-10. The scientists came to a conclusion that prescribing immune modulators which reduce the expression of the local inflammatory reaction by reducing the amount of inflammatory cytokines and increasing the amount of anti inflammatory cytokines in the blood during the acute stage of the disease helps the betterment of the patients. In the opinion of the researchers, their discovery will make the treatment of patients more effective.